Niowave and Ratio Therapeutics announce Ac-225 supply agreement for radioligand therapy

Niowave will supply Ratio Therapeutics with actinium-225 (Ac-225) for targeted alpha therapy development. The agreement secures domestic isotope production for Ratio's radioligand pipeline, though specific financial terms or volumes were not disclosed in the source.

• This is an industry supply announcement from AuntMinnie, reported at the trade layer, not a peer-reviewed study.
• Ac-225 is a high-demand alpha emitter used in targeted radioligand therapies for cancer; domestic supply has been a bottleneck.
• No clinical data, trial timelines, or specific therapeutic candidates were detailed in the available snippet.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.